SCHEMBL505931

SCHEMBL505931

CC1[CH]CC(C)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1920259 1.00
SCHEMBL1920338 1.00
SCHEMBL10580444 0.82
SCHEMBL16617206 0.75
SCHEMBL16617782 0.75
SCHEMBL38170 0.75
SCHEMBL10584777 0.73
SCHEMBL5686142 0.72
SCHEMBL575091 0.71
SCHEMBL1921197 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117983302-A Catalyst containing ferrocene PNP ligand for ethylene selective tetramerization and preparation method and application thereof 华东理工大学 2024-05-07 CN claimed
CN-103969863-B Liquid crystal display device 三星显示有限公司 2018-09-25 CN claimed
US-7858641-B2 melanocortin-4 receptor (MC4-R) agonists such as (3R,5S)-N-(2-{2-[2-fluoro-4-(methyloxy)phenyl]ethyl}-1-oxo-1,2-dihydroisoquinolin-6-yl)-3,5-dimethyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide, used for the treatment of obesity or diabetes NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-12-28 US claimed
US-7456183-B2 Guanidino compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-11-25 US claimed
US-7442698-B2 Substituted heterocyclic compounds and methods of use AMGEN INC. (US) 2008-10-28 US claimed
US-7189727-B2 Guanidino compounds CHIRON CORPORATION (US) 2007-03-13 US claimed
EP-1385823-B1 GUANIDINO COMPOUNDS AS MELANOCORTIN-4 RECEPTOR (MC4-R) AGONISTS CHIRON CORP (US) 2006-12-13 EP claimed
EP-1654238-A1 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AMGEN INC. (US) 2006-05-10 EP claimed
US-6960582-B2 Guanidino compounds CHIRON CORPORATION (US) 2005-11-01 US claimed
US-20050124652-A1 Guanidino compounds BOYCE RUSTUM (US) 2005-06-09 US claimed
WO-2005009978-A1 2-AMINOPYRIMIDINE AND 2-AMINOPYRIDINE-4-CARBAMATES FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AMGEN INC. (US) 2005-02-03 WO claimed
US-20050026914-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2005-02-03 US claimed
US-20040248895-A1 Novel guanidino compounds CHU DANIEL (US) 2004-12-09 US claimed
EP-1478626-A2 GUANIDINO COMPOUNDS CHIRON CORPORATION (US) 2004-11-24 EP claimed
US-6716840-B2 AGONISTS OF THE MELANOCORTIN-4 RECEPTOR (?MC-4R?); USEFUL TREATING OBESITY AND TYPE 2 DIABETES CHIRON CORPORATION 2004-04-06 US claimed
US-20040024211-A1 Novel guanidino compounds CHIRON CORPORATION 2004-02-05 US claimed
US-20030195187-A1 Guanidino compounds CHIRON CORPORATION 2003-10-16 US claimed
WO-2003066597-A2 GUANIDINO COMPOUNDS CHIRON CORPORATION (US) 2003-08-14 WO claimed
US-6410497-B1 DETERGENTS; BLEACHES; ANTISEPTICS BASF AKTIENGESELLSCHAFT (DE) 2002-06-25 US claimed
US-6071846-A OLEFIN POLYMERIZATION CATALYST WHICH ALLOWS A POLYOLEFIN TO HAVE HIGH STEREOREGULARITY AND HIGH POLYMERIZATION ACTIVITY; SOLID TITANIUM CATALYST COMPONENT COMPRISES A MAGNESIUM ATOM, TITANIUM ATOM, HALOGEN ATOM AND ELECTRON DONOR TOKUYAMA CORPORATION (JP) 2000-06-06 US claimed